Embecta (NASDAQ: EMBC) — Perfil da empresa, notícias e dados financeiros
Embecta specializes in diabetes management products, focusing on innovative technologies for individuals and healthcare professionals.
Embecta
Embecta (NASDAQ:EMBC) specializes in the development, manufacturing, and sale of diabetes management products and solutions. The company focuses on delivering innovative technologies and services to support individuals managing diabetes and healthcare professionals in providing care. Embecta's projects span across various facets of diabetes care, including blood glucose monitoring systems and insulin delivery devices. The company aims to enhance the quality of life for people affected by diabetes through their comprehensive suite of products, ensuring accessibility, ease of use, and reliability. With a strong commitment to research and development, Embecta continually strives to advance its offerings and expand its reach in the global healthcare market to meet the evolving needs of the diabetes community.
Resumo
Operações
Produtos e/ou serviços de Embecta
- Insulin delivery devices, which include a wide range of solutions for diabetes management, enhancing patient experience and control over their condition.
- Continuous glucose monitoring (CGM) systems, providing real-time blood glucose level tracking to assist patients in managing diabetes more effectively.
- Software solutions for diabetes management, offering tools and apps designed to simplify monitoring, reporting, and decision-making processes for both patients and healthcare providers.
- Diabetes care accessories, which encompass a variety of products meant to support the daily management of diabetes, including carrying cases and skin preparation items.
- Educational resources and support programs aimed at empowering patients with information and guidance on diabetes management, promoting better health outcomes.
- Research and development initiatives focused on advancing diabetes care technologies, seeking to innovate and improve the effectiveness and convenience of diabetes management tools and therapies.
equipe executiva do Embecta
- Devdatt KurdikarPresident, CEO & Chairman
- Jacob P. ElguiczeSenior VP & CFO
- Jeffrey Z. MannSenior VP, General Counsel, Head of Business Development & Corporate Secretary
- Jean M. CasnerSenior VP & Chief Human Resources Officer
- Shaun CurtisSenior Vice President of Global Manufacturing & Supply Chain
- Anthony M. RothVP, Chief Accounting Officer & Corporate Controller
- Pravesh KhandelwalVP & Head of Investor Relations
- Ginny BlockiSenior Vice President of Strategy
- Tom BlountSenior VP & President of North America
- Slobodan RadumiloSenior VP & President of International
Histórico de dividendos
Dividendos por ação pagos pela Embecta , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026 | — | — | — | $0.3200 |
| FY2025 | — | — | — | $0.6000 |
| FY2024 | — | — | — | $0.6000 |
| FY2023 | — | — | — | $0.6000 |
| FY2022 | — | — | — | $0.1500 |
Principais indicadores financeiros
Resultados divulgados pela Embecta , em USD.
- Cap. de mercado
- 366 mi
- Receita (TTM)
- 1 bi
- P/L
- 4.4
- LPA (diluído, TTM)
- 1.5
- Dividend yield
- 7.0%
- Margem de lucro
- 8.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,1 bi | 329,3 mi | 95,4 mi | |
| 1,1 bi | 174,2 mi | 78,3 mi | |
| 1,1 bi | 229,6 mi | 70,4 mi | |
| 1,1 bi | 378,1 mi | 223,6 mi |